Document is current
Any future updates will be listed below
-
Authors
Boger, Ron S. https://orcid.org/0000-0002-4467-271X
Chithrananda, Seyone https://orcid.org/0000-0002-3671-9135
Angelopoulos, Anastasios N. https://orcid.org/0000-0001-9787-0579
Yoon, Peter H.
Jordan, Michael I. https://orcid.org/0000-0001-8935-817X
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (D-001)
- License Information
-
More Information
Article History
Received: 12 July 2024
Accepted: 20 December 2024
First Online: 2 January 2025
Competing interests
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences and Scribe Therapeutics, and a director of Altos, Johnson & Johnson and Tempus. J.A.D. is a scientific advisor to Caribou Biosciences, Intellia Therapeutics, Mammoth Biosciences, Inari, Scribe Therapeutics, Felix Biosciences and Algen. J.A.D. also serves as Chief Science Advisor to Sixth Street and a Scientific Advisory Board member at The Column Group. J.A.D. conducts academic research projects sponsored by Roche and Apple Tree Partners. The remaining authors declare no competing interests.
